Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CDK9 | P50750 | 10/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4109227 | 0.86 | USP2 (0.72) | CYP1A2CYP2D6CYP2C19CLK4ALDH1A1 | |
| SCHEMBL3141056 | 0.82 | CCNT1 (0.45) | CYP1A2CYP2D6CYP2C19CLK4ALDH1A1 | |
| SCHEMBL4103152 | 0.79 | CYP1A2 (0.53) | CYP1A2CYP2D6CYP2C19CLK4ALDH1A1 | |
| SCHEMBL4101911 | 0.78 | USP2 (0.71) | CYP1A2CYP2D6CYP2C19CLK4ALDH1A1 | |
| SCHEMBL4108496 | 0.78 | USP2 (0.52) | CYP1A2CYP2D6CYP2C19CLK4ALDH1A1 | |
| SCHEMBL4109385 | 0.77 | CDK9 (0.51) | CYP1A2CYP2D6CYP2C19CLK4ALDH1A1 | |
| SCHEMBL4710503 | 0.77 | USP2 (0.72) | CYP1A2CYP2D6CYP2C19CLK4ALDH1A1 | |
| SCHEMBL4101983 | 0.77 | USP2 (0.72) | CYP1A2CYP2D6CYP2C19CLK4ALDH1A1 | |
| SCHEMBL4105833 | 0.76 | USP2 (0.71) | CYP1A2CYP2D6CYP2C19CLK4ALDH1A1 | |
| SCHEMBL4107424 | 0.76 | CDK9 (0.65) | CYP1A2CYP2D6CYP2C19CLK4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678147-B1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | LEAD DISCOVERY CENTER GMBH (DE) | 2012-08-08 | — | — | EP | claimed |
| US-20090221581-A1 | Methods of treating pain | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | claimed |
| EP-1678147-A1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | GPC Biotech AG (DE) | 2006-07-12 | — | — | EP | claimed |
| WO-2005026129-A1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | GPC BIOTECH AG (DE) | 2005-03-24 | — | — | WO | claimed |
| US-8084457-B2 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | LEAD DISCOVERY CENTER GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20090221581-A1 | Methods of treating pain | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| EP-1901747-A2 | PYRIMIDINE-BASED CDK INHIBITORS FOR TREATING PAIN | Ingenium Pharmaceuticals AG (DE) | 2008-03-26 | — | — | EP | disclosed |
| US-20070191344-A1 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2006125616-A2 | PYRIMIDINE-BASED CDK INHIBITORS FOR TREATING PAIN | INGENIUM PHARMACEUTICALS AG (DE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191344-A1 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | DAPK1, DUSP4, MARK4 | CYP1A2 4187/4885CYP2D6 2758/4885CYP2C19 3092/4885 |
| US-20090221581-A1 | Methods of treating pain | CDK5, CAMKK2, CDK3 | CYP1A2 4521/4885CYP2D6 4660/4885CYP2C19 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.